Decibel Therapeutics Inc is a biotechnology business based in the US. Decibel Therapeutics shares (DBTX) are listed on the NASDAQ and all prices are listed in US Dollars. Decibel Therapeutics employs 40 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Experienced Investors
Our top pick for
Large Accounts
| Latest market close | $7.47 |
|---|---|
| 52-week range | $6.18 - $24.39 |
| 50-day moving average | $8.00 |
| 200-day moving average | $8.21 |
| Wall St. target price | $24.50 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.26 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.47 from 2021-10-20
| 1 week (2021-10-14) | -0.53% |
|---|---|
| 1 month (2021-09-21) | -10.86% |
| 3 months (2021-07-21) | 3.89% |
| 6 months (2021-04-21) | -25.67% |
| 1 year (2020-10-17) | N/A |
|---|---|
| 2 years (2019-10-17) | N/A |
| 3 years (2018-10-17) | N/A |
| 5 years (2016-10-17) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -40.97% |
| Return on equity TTM | -145.27% |
| Profit margin | 0% |
| Book value | $6.81 |
| Market capitalisation | $188.2 million |
TTM: trailing 12 months
There are currently 267,384 Decibel Therapeutics shares held short by investors – that's known as Decibel Therapeutics's "short interest". This figure is 44.4% down from 481,088 last month.
There are a few different ways that this level of interest in shorting Decibel Therapeutics shares can be evaluated.
Decibel Therapeutics's "short interest ratio" (SIR) is the quantity of Decibel Therapeutics shares currently shorted divided by the average quantity of Decibel Therapeutics shares traded daily (recently around 49978.317757009). Decibel Therapeutics's SIR currently stands at 5.35. In other words for every 100,000 Decibel Therapeutics shares traded daily on the market, roughly 5350 shares are currently held short.
To gain some more context, you can compare Decibel Therapeutics's short interest ratio against those of similar companies.
However Decibel Therapeutics's short interest can also be evaluated against the total number of Decibel Therapeutics shares, or, against the total number of tradable Decibel Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Decibel Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Decibel Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.024% of the tradable shares (for every 100,000 tradable Decibel Therapeutics shares, roughly 24 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Decibel Therapeutics.
Find out more about how you can short Decibel Therapeutics stock.
We're not expecting Decibel Therapeutics to pay a dividend over the next 12 months.
Decibel Therapeutics, Inc. , a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.